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Methods 
Cell Cycle Analysis: Cells were seeded in 6-well plates overnight, then treated with 
the indicated doses of Navitoclax or Venetoclax. After 72 hours, cells were harvested, 
stained with propidium iodide, and cell cycle analysis was performed3
Cell Viability: Cells were seeded in 96 well plates then treated with Navitoclax and 
Venetoclax. Cell viability was evaluated after 72 hours (3 days)
Cell Growth: Cells were seeded in 96 well plates then cell growth was evaluated over 
a period of 5 days
Cell Energetics: Cells were seeded in Seahorse XF assay plates and mito stress test 
was performed following the manufacturer’s instructions
Results
Hypotheses 
• BCLXL-upregulated cells will demonstrate a greater rate of growth than parental. 
BCLXS-upregulated cells will have the inverse effect, based on prior evidence in 
other cancers
• Navitoclax will induce greater cell death in BCLXL-upregulated cells, but not in 
BCLXS-upregulated cells
• BCLXL and BCLXS will have opposite effects on mitochondrial energetics, based on 
prior evidence of their opposite tumorigenetical effects on other cancers
Conclusions 
• BCLXL upregulation had a negative 
effect on cell growth as well as drug 
sensitivity relative to parental cells, 
going against its previously 
documented tumorigenic role in 
other cancers
• BCLXS upregulation had a positive 
effect on cell growth and a negative 
effect on drug sensitivity relative to 
parental cells going against its 
previously documented tumor 
suppressive role in other cancers
• BCLXS-upregulated cells had lower 
drug sensitivity than BCLXL-
upregulated cells
• BCLXL upregulation caused a 
decrease in apoptosis following 
BCL2 inhibitor drug treatment, and 
BCLXS upregulation caused an 
even greater decrease
• BCLXL upregulation caused a 
decrease in cell respiration and 
glycolysis
• BCXLS upregulation also caused a 
decrease in cell respiration and 
glycolysis
• Considering the data, BCLXL and 
BCLXS likely play differential roles in 
cutaneous melanoma as compared 
to other cancers
• Results may be partially due to 
WM4257’s low levels of BCL2 
expression levels – research is 
needed on high-BCLX expression 
cell lines
Background
• Cutaneous melanoma is the most 
aggressive form of skin cancer
• Immunotherapies and single-agent 
targeted therapies have high relapse 
rates
• 70% of cutaneous melanoma patients 
have increased expression of BCL2 
family proteins (e.g. BCL2 and MCL1) 
that prevent apoptosis1
• Although BCLXL and BCLXS are 
respectively described as anti-apoptotic 
and pro-apoptotic proteins in other 
cancers, their roles are not well 
understood in melanoma
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Cell cycle analysis of parental and BCLXL or BCLXS over-expressing cells
Cell Viability after Single-Agent Treatment
Figure 1. Apoptosis Pathway2
Figure 3. Parental 
4257 cells were the 














Figure 2. BCLXL-upregulated cells demonstrated less sub-G1 phase than parental when treated with 10 uM of Navitoclax. BCLXS-upregulated cells demonstrated even less 
sub-G1 phase than BCLXL-upregulated cells when treated with 10 uM of Navitoclax. The same patterns are seen with Venetoclax, with 10 uM causing less sub-G1 phase for 
BCLXL-upregulated cells and even less sub-G1 phase for BCLXS-upregulated cells. A G2/M spike was seen in BCLXL cells treated with 1 uM Navitoclax, however no similar 











going against the 
currently known 
role of BCL-XS as 
described in 
literature as a 
tumor 
suppressor. 
• BCL2 is a marker of chemotherapy treatment resistance and a marker of 
response to BCL2 inhibitors such as Venetoclax and Navitoclax - however, the 
role of BCLXL in treatment response is not known, especially in melanoma
• Shorter and potentially antagonistic isoform, BCLXS, has not been studied in 
melanoma
• Navitoclax targets BCL2 and BCLXL, while Venetoclax solely targets BCL2
• Navitoclax’s action on BCLXS is unknown
Generating Cell Lines 
• One BCLXL-upregulated cell line clone and one BCLXS-upregulated cell line clone 
were engineered from the low-BCL2-expressing melanoma cell line WM4257 via 
lentiviral constructs
• Clones were made to be puromycin resistant.
Cell Energetic Profiles






















































































































rates as compared to 
parental. As typical 
melanoma tumors’ 
OCR levels are over 
100, this assay is 
being re-run.
